Dual immune checkpoint inhibitors (the combination of anti-PD-1 and anti-CTLA-4 therapy) is considered as a promising therapy to enhance ICI efficacy and showed improved prognosis in melanoma and NSCLC (139, 197). This evidence concerns the gene CTLA4 and melanoma.